Glycorex Transplantation

Glycorex Transplantation AB is a medical technology company specializing in blood group-compatible transplants, universal blood plasma, and autoimmune disease treatment using extracorporeal blood therapy.

Their core technology, Glycosorb-ABO, enables transplants across blood group barriers, and they also develop products for universal blood plasma preparation and treatment of conditions like Myasthenia gravis.

Founded in 1996, Glycorex is based in Lund, Sweden. The company is actively involved in research and development, constantly working to improve and expand the applications of their technology. Glycorex has an established presence in the market, with their products being used worldwide.

Glycorex's main product, Glycosorb-ABO, allows for transplants between individuals with incompatible blood types, significantly expanding the donor pool and improving transplant outcomes.

This technology specifically targets and removes anti-A and anti-B antibodies, enabling ABO-incompatible transplants.

Glycosorb-ABO has been used in over 3,500 blood group incompatible transplants, demonstrating excellent clinical results.

For more information on Glycosorb-ABO, please email us at contact@epg.com.sg.

‍